JP2010508834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508834A5 JP2010508834A5 JP2009535633A JP2009535633A JP2010508834A5 JP 2010508834 A5 JP2010508834 A5 JP 2010508834A5 JP 2009535633 A JP2009535633 A JP 2009535633A JP 2009535633 A JP2009535633 A JP 2009535633A JP 2010508834 A5 JP2010508834 A5 JP 2010508834A5
- Authority
- JP
- Japan
- Prior art keywords
- core
- cells
- positive
- binding
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 244000005700 microbiome Species 0.000 claims description 138
- 239000000203 mixture Substances 0.000 claims description 117
- 210000004443 dendritic cell Anatomy 0.000 claims description 109
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 65
- 239000006166 lysate Substances 0.000 claims description 65
- 238000009472 formulation Methods 0.000 claims description 64
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical group OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 59
- 210000002865 immune cell Anatomy 0.000 claims description 48
- 230000009089 cytolysis Effects 0.000 claims description 46
- 230000028996 humoral immune response Effects 0.000 claims description 45
- 241001465754 Metazoa Species 0.000 claims description 43
- 210000002966 serum Anatomy 0.000 claims description 41
- 108010028495 asialoglycophorin Proteins 0.000 claims description 40
- 230000028327 secretion Effects 0.000 claims description 40
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 36
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 36
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 36
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 230000024932 T cell mediated immunity Effects 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 241000606125 Bacteroides Species 0.000 claims description 23
- 238000012258 culturing Methods 0.000 claims description 23
- 210000002381 plasma Anatomy 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 claims description 16
- 229910052693 Europium Inorganic materials 0.000 claims description 16
- 102000028180 Glycophorins Human genes 0.000 claims description 16
- 108091005250 Glycophorins Proteins 0.000 claims description 16
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 8
- 239000012642 immune effector Substances 0.000 claims description 8
- 238000010166 immunofluorescence Methods 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 230000037452 priming Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000217846 Bacteroides caccae Species 0.000 claims description 2
- 241000588923 Citrobacter Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000186394 Eubacterium Species 0.000 claims description 2
- 241001617393 Finegoldia Species 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims 6
- 150000001720 carbohydrates Chemical group 0.000 claims 5
- 238000004090 dissolution Methods 0.000 claims 4
- 230000004044 response Effects 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 241001569772 Celithemis elisa Species 0.000 claims 1
- 241000853331 Eggerella Species 0.000 claims 1
- 241000604373 Ovatus Species 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 210000001728 clone cell Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000035943 smell Effects 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 241000193818 Atopobium Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001657509 Eggerthella Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000159562 Johnsonella Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06090209A EP1920782A1 (en) | 2006-11-10 | 2006-11-10 | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
| EP06090208.7A EP1920781B1 (en) | 2006-11-10 | 2006-11-10 | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| PCT/EP2007/009766 WO2008055703A2 (en) | 2006-11-10 | 2007-11-12 | Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075105A Division JP2015134813A (ja) | 2006-11-10 | 2015-04-01 | 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508834A JP2010508834A (ja) | 2010-03-25 |
| JP2010508834A5 true JP2010508834A5 (https=) | 2011-01-06 |
Family
ID=39200183
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535632A Expired - Fee Related JP5771355B2 (ja) | 2006-11-10 | 2007-11-12 | 微生物およびその部分が誘導する炭水化物特異的細胞性免疫 |
| JP2009535633A Withdrawn JP2010508834A (ja) | 2006-11-10 | 2007-11-12 | 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 |
| JP2015074801A Withdrawn JP2015133979A (ja) | 2006-11-10 | 2015-04-01 | 微生物およびその部分が誘導する炭水化物特異的細胞性免疫 |
| JP2015075105A Withdrawn JP2015134813A (ja) | 2006-11-10 | 2015-04-01 | 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535632A Expired - Fee Related JP5771355B2 (ja) | 2006-11-10 | 2007-11-12 | 微生物およびその部分が誘導する炭水化物特異的細胞性免疫 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015074801A Withdrawn JP2015133979A (ja) | 2006-11-10 | 2015-04-01 | 微生物およびその部分が誘導する炭水化物特異的細胞性免疫 |
| JP2015075105A Withdrawn JP2015134813A (ja) | 2006-11-10 | 2015-04-01 | 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9494587B2 (https=) |
| EP (4) | EP1920781B1 (https=) |
| JP (4) | JP5771355B2 (https=) |
| KR (2) | KR20150054014A (https=) |
| CN (1) | CN101573138B (https=) |
| AU (2) | AU2007316820B2 (https=) |
| BR (2) | BRPI0719005A2 (https=) |
| CA (2) | CA2668704A1 (https=) |
| EA (1) | EA025395B1 (https=) |
| ES (1) | ES2715045T3 (https=) |
| IL (2) | IL198567A0 (https=) |
| MX (1) | MX2009005004A (https=) |
| NO (1) | NO20091748L (https=) |
| NZ (1) | NZ577559A (https=) |
| PL (1) | PL1920781T3 (https=) |
| RU (1) | RU2460074C2 (https=) |
| WO (2) | WO2008055703A2 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| EP1920781B1 (en) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| EP2119365B1 (de) | 2008-05-13 | 2017-08-16 | Glycotope GmbH | Fermentationsprozess |
| AR071787A1 (es) | 2008-05-13 | 2010-07-14 | Glycotope Gmbh | Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento |
| US20120190025A1 (en) * | 2009-07-27 | 2012-07-26 | Angelia Denene Blackwood | Enterococcus and fecal bacteroides for rapid water quality assessment |
| GB2475226A (en) | 2009-11-03 | 2011-05-18 | Genetic Analysis As | Universal Prokaryote 16S ribosome PCR primer pair |
| AU2011261528A1 (en) * | 2010-06-01 | 2013-01-10 | Moore Research Enterprises Llc | Cellular constituents from Bacteroides, compositions thereof, and therapeutic methods employing Bacteroides or cellular constituents thereof |
| WO2012045150A1 (en) * | 2010-10-04 | 2012-04-12 | British Columbia Cancer Agency Branch | Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| JP2014524260A (ja) * | 2011-08-22 | 2014-09-22 | グリコトープ ゲーエムベーハー | Ｂａｃｔｅｒｏｉｄｅｓｘｙｌａｎｉｓｏｌｖｅｎｓ種の微生物 |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2014001658A1 (fr) * | 2012-06-26 | 2014-01-03 | Centre Hospitalier Régional Universitaire De Lille | Méthode de diagnostic in vitro d'une infection fongique invasive par spectrométrie de masse maldi-tof |
| CN102813916B (zh) * | 2012-09-05 | 2015-03-11 | 北京希普生国际生物医学研究院 | 一种快速获取树突状细胞疫苗的制备方法及其应用 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| WO2015020765A2 (en) * | 2013-08-06 | 2015-02-12 | Trustees Of Dartmouth College | Unglycosylated lysostaphin variant protein |
| CA2941029C (en) | 2014-04-10 | 2021-02-16 | Obi Pharma Inc. | Antibodies, pharmaceutical compositions and uses thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CN104546932A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| CN104546933A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| SG11201704814SA (en) * | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
| WO2016123313A1 (en) | 2015-01-29 | 2016-08-04 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| HRP20191949T1 (hr) | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| HK1254843B (zh) | 2015-11-20 | 2020-04-17 | 希杰生物科技株式会社 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| EP3478093A4 (en) * | 2016-07-01 | 2020-03-04 | Evolve Biosystems, Inc. | METHOD FOR ELEVATING THE MATURATION OF THE MAMMAL IMMUNE SYSTEM |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3378949A1 (en) * | 2017-03-22 | 2018-09-26 | Assistance Publique - Hôpitaux de Paris | Method for determining the potential efficacy of anticancer treatment |
| ES2877726T3 (es) | 2017-05-22 | 2021-11-17 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| TWI812624B (zh) | 2017-06-14 | 2023-08-21 | 南韓商希杰生物科技股份有限公司 | 包含細菌品系之組成物 |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| MA51770A (fr) | 2017-07-05 | 2020-05-13 | Evelo Biosciences Inc | Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis |
| TWI842710B (zh) * | 2018-05-11 | 2024-05-21 | 台灣浩鼎生技股份有限公司 | 預測人體免疫反應的方法 |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| EP3870691A4 (en) | 2018-09-13 | 2022-09-07 | Xbiome Inc. | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS |
| CA3146738A1 (en) * | 2019-07-18 | 2021-01-21 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase-based treatments of metabolic disorders |
| KR20220137045A (ko) * | 2020-02-03 | 2022-10-11 | 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. | 미생물을 단리하는 방법 |
| CN115992084A (zh) * | 2022-08-18 | 2023-04-21 | 吉林农业大学 | 表达牛巨噬细胞粒细胞集落刺激因子的重组乳酸菌及应用 |
| WO2026078981A1 (ja) * | 2024-10-08 | 2026-04-16 | キリンホールディングス株式会社 | 免疫賦活能を有する細菌及びそれを含有する組成物 |
| JP7838165B1 (ja) * | 2024-10-08 | 2026-03-31 | キリンホールディングス株式会社 | 免疫賦活能を有する細菌及びそれを含有する組成物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4672316A (en) | 1983-08-19 | 1987-06-09 | Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag | Method for calibrating a muzzle velocity measuring device |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| US4931275A (en) * | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
| US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
| EP0433299B1 (en) | 1988-08-02 | 1998-05-06 | Gastro Services Pty. Limited (ACN 002 994 890) | Treatment of gastro-intestinal disorders |
| US5110911A (en) | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
| ATE241011T1 (de) | 1991-02-27 | 2003-06-15 | Micromet Ag | Serin-reiche peptidlinker |
| EP0636029B1 (en) | 1992-04-13 | 2000-11-08 | Dana-Farber Cancer Institute, Inc. | Antibodies specific for carcinoma-associated antigens |
| US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
| CA2164088C (en) | 1993-06-07 | 2005-06-14 | Gary J. Nabel | Plasmids suitable for gene therapy |
| DE4329004A1 (de) | 1993-08-28 | 1995-03-09 | Max Delbrueck Centrum | Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis |
| US7137011B1 (en) | 1993-09-01 | 2006-11-14 | Sandisk Corporation | Removable mother/daughter peripheral card |
| US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| JP2660175B2 (ja) * | 1994-10-19 | 1997-10-08 | 北海道 | キクイモ由来のレクチンおよびその分離精製法 |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US5939404A (en) * | 1995-12-27 | 1999-08-17 | Ngk Insulators, Ltd. | Cancer metastasis inhibitor containing a streptococcus agalactiae Ia type or Ib type surface polysaccharide as a main ingredient |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| WO1997040182A1 (de) | 1996-04-19 | 1997-10-30 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
| DE69815707T2 (de) * | 1997-11-20 | 2004-07-01 | Vical, Inc., San Diego | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| BR9909220A (pt) * | 1998-02-20 | 2000-11-21 | Tanox Inc | Inibidores de ativação de complemento |
| JP2000028599A (ja) * | 1998-04-15 | 2000-01-28 | Ebara Corp | Ｄ―マンノ―ス識別アフィニティ―担体とその使用方法 |
| WO2000052135A2 (en) | 1999-03-02 | 2000-09-08 | Human Genome Sciences, Inc. | Engineering intracellular sialylation pathways |
| DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
| WO2001023421A2 (en) * | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
| EP1458242A4 (en) * | 2001-07-06 | 2006-06-07 | Sloan Kettering Inst Cancer | COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER |
| US20050042714A1 (en) | 2001-08-17 | 2005-02-24 | Michael Pawlita | Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
| DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
| GB0125473D0 (en) | 2001-10-24 | 2001-12-12 | Syngenta Ltd | Chemical process |
| CN1201817C (zh) * | 2001-11-09 | 2005-05-18 | 北京大学肝病研究所 | 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法 |
| WO2003044051A1 (en) | 2001-11-20 | 2003-05-30 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AU2003266236A1 (en) * | 2002-07-22 | 2004-02-09 | Nemod Immuntherapie Ag | Method for the production of an immunostimulating mucin (muc1) |
| SI1530628T1 (sl) * | 2002-08-16 | 2011-02-28 | Glycotope Gmbh | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine |
| WO2004029621A2 (en) * | 2002-09-26 | 2004-04-08 | Novartis Ag | Tcell mediator/modulator assay based upon tcell restricted transgenic mouse |
| DE10256900A1 (de) * | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| ES2321939T3 (es) * | 2003-02-27 | 2009-06-15 | Northwest Biotherapeutics, Inc. | Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales. |
| GB0315991D0 (en) | 2003-07-08 | 2003-08-13 | Dakocytomation Denmark As | Standard |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| ES2425475T3 (es) | 2003-08-18 | 2013-10-15 | Glycotope Gmbh | Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas |
| FR2861080B1 (fr) | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| EP1725673A1 (en) | 2004-02-13 | 2006-11-29 | Glycotope Gmbh | Sialytated glycoproteins-process conditions and an efficient method for their production |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| JP2008505130A (ja) * | 2004-07-01 | 2008-02-21 | ケベンハウンス・ウニヴェルジテート | レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法 |
| EP1789027B1 (en) * | 2004-07-26 | 2013-09-04 | The Research Foundation Of State University Of New York | Therapeutic use of anti-tf-antigen antibody |
| JP5313672B2 (ja) * | 2005-08-01 | 2013-10-09 | ハー マジェスティ ザ クイーン イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ | 高オレイン酸低リノレン酸油を含む、低繊維黄色キャノーラ種子 |
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| EP1920781B1 (en) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
| AR071787A1 (es) * | 2008-05-13 | 2010-07-14 | Glycotope Gmbh | Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| ES2686313T3 (es) * | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
-
2006
- 2006-11-10 EP EP06090208.7A patent/EP1920781B1/en active Active
- 2006-11-10 EP EP06090209A patent/EP1920782A1/en not_active Withdrawn
- 2006-11-10 PL PL06090208T patent/PL1920781T3/pl unknown
-
2007
- 2007-11-12 EA EA200970471A patent/EA025395B1/ru not_active IP Right Cessation
- 2007-11-12 EP EP07819754A patent/EP2101814A1/en not_active Withdrawn
- 2007-11-12 AU AU2007316820A patent/AU2007316820B2/en not_active Ceased
- 2007-11-12 JP JP2009535632A patent/JP5771355B2/ja not_active Expired - Fee Related
- 2007-11-12 MX MX2009005004A patent/MX2009005004A/es active IP Right Grant
- 2007-11-12 US US12/514,248 patent/US9494587B2/en not_active Expired - Fee Related
- 2007-11-12 WO PCT/EP2007/009766 patent/WO2008055703A2/en not_active Ceased
- 2007-11-12 US US12/514,200 patent/US8592165B2/en not_active Expired - Fee Related
- 2007-11-12 KR KR1020157011383A patent/KR20150054014A/ko not_active Abandoned
- 2007-11-12 KR KR1020097011972A patent/KR20090080554A/ko not_active Abandoned
- 2007-11-12 NZ NZ577559A patent/NZ577559A/en not_active IP Right Cessation
- 2007-11-12 CA CA002668704A patent/CA2668704A1/en not_active Abandoned
- 2007-11-12 EP EP07819755.5A patent/EP2099480B2/en active Active
- 2007-11-12 BR BRPI0719005-0A patent/BRPI0719005A2/pt not_active IP Right Cessation
- 2007-11-12 RU RU2009122204/10A patent/RU2460074C2/ru not_active IP Right Cessation
- 2007-11-12 CN CN200780049283.7A patent/CN101573138B/zh not_active Expired - Fee Related
- 2007-11-12 CA CA002668603A patent/CA2668603A1/en not_active Abandoned
- 2007-11-12 JP JP2009535633A patent/JP2010508834A/ja not_active Withdrawn
- 2007-11-12 WO PCT/EP2007/009765 patent/WO2008055702A1/en not_active Ceased
- 2007-11-12 BR BRPI0718796-3A2A patent/BRPI0718796A2/pt not_active IP Right Cessation
- 2007-11-12 AU AU2007316819A patent/AU2007316819B2/en not_active Ceased
- 2007-11-12 ES ES07819755T patent/ES2715045T3/es active Active
-
2009
- 2009-05-04 NO NO20091748A patent/NO20091748L/no not_active Application Discontinuation
- 2009-05-05 IL IL198567A patent/IL198567A0/en unknown
- 2009-05-07 IL IL198626A patent/IL198626A/en not_active IP Right Cessation
-
2015
- 2015-04-01 JP JP2015074801A patent/JP2015133979A/ja not_active Withdrawn
- 2015-04-01 JP JP2015075105A patent/JP2015134813A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508834A5 (https=) | ||
| JP2015134813A5 (https=) | ||
| US12350298B2 (en) | Microbiome related immunotherapies | |
| Bai et al. | Prodrug‐based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death | |
| Shih et al. | Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells | |
| JP2020503862A (ja) | Ｃｄ８＋ ｔ細胞の誘導のための組成物および方法 | |
| JP2020530493A (ja) | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 | |
| JP2020530494A (ja) | 健康な腸バリアを維持及び回復するための組成物及び方法 | |
| JP2005523277A (ja) | 癌の治療 | |
| KR102833272B1 (ko) | 변형된 효모-브라큐리 면역치료학적 조성물 | |
| JP2021512638A (ja) | Ｃｄ８＋ｔ細胞の誘導のための組成物および方法 | |
| WO2007097358A1 (ja) | Ｈｌａ－ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| KR20220128362A (ko) | 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태 | |
| EP4076482A1 (en) | Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same | |
| JP2011516471A (ja) | 腫瘍性疾患を治療するための組成物および方法 | |
| JP2015520129A (ja) | 多価乳がんワクチン | |
| KR20230004619A (ko) | 붕해 프로파일이 개선된 고체 투여 형태 | |
| US20240316122A1 (en) | Methods of treating cancer using recombinant microorganisms expressing a sting agonist | |
| Azimi et al. | Intestinal microbiota: novel personalized cancer immunotherapy in colorectal cancer | |
| Wang et al. | Akkermania muciniphila: a rising star in tumor immunology | |
| JP4780540B2 (ja) | サバイビン由来癌抗原ペプチド | |
| TWI674108B (zh) | 索脊瘤之以酵母菌爲基礎之免疫療法 | |
| TW202322787A (zh) | 包含細菌和微生物胞外囊泡之固體劑型 | |
| JP2007525473A (ja) | 単球由来の自己寛容誘導性自家細胞および薬学的組成物におけるその使用 | |
| EP4721750A1 (en) | Nutraceutical formulation for use in cancer immunotherapy |